Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan I Silverberg

Showing results (451-460 of 670) with videos related to

Pageof 67
Sort By:
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|November 10, 2023
Abrocitinib efficacy and safety in moderate-to-severe atopic dermatitis by race, ethnicity, and Fitzpatrick skin typeAndrew F Alexis, Jonathan I Silverberg, Zakiya P Rice, et al.
Journal of the American Academy of Dermatology|February 21, 2021
Metformin is associated with decreased risk of basal cell carcinoma: A whole-population case-control study from IcelandJonas A Adalsteinsson, Sonal Muzumdar, Reid Waldman, et al.
Journal of the American Academy of Dermatology|September 16, 2022
Itch-free state in patients with atopic dermatitis treated with ruxolitinib cream: A pooled analysis from two randomized phase 3 studiesAndrew Blauvelt, Jacek C Szepietowski, Kim Papp, et al.
Journal of the American Academy of Dermatology|February 18, 2026
The 487-gene expression profile test guides systemic therapy selection to improve outcomes for patients with atopic dermatitis: Results from a prospective trialJonathan I Silverberg, Lawrence F Eichenfield, April W Armstrong, et al.
The Journal of Dermatological Treatment|September 25, 2024
Disease burden and patient characteristics associated with systemic therapy utilization among adults with atopic dermatitis: data from CorEvitas Atopic Dermatitis RegistryJonathan I Silverberg, Linda Stein Gold, Seemal Desai, et al.
Journal of the American Academy of Dermatology|November 29, 2020
Anti-tumor necrosis factor therapy is associated with increased in situ squamous cell carcinoma of the skin: A population-based case-control studyJonas A Adalsteinsson, Sonal Muzumdar, Reid Waldman, et al.
Eclinicalmedicine|July 3, 2023
Efficacy and safety of topically applied therapeutic ammonia oxidising bacteria in adults with mild-to-moderate atopic dermatitis and moderate-to-severe pruritus: a randomised, double-blind, placebo-controlled, dose-ranging, phase 2b trialJonathan I Silverberg, Peter A Lio, Eric L Simpson, et al.
Dermatology and Therapy|April 18, 2022
Comparative Efficacy of Targeted Systemic Therapies for Moderate to Severe Atopic Dermatitis without Topical Corticosteroids: Systematic Review and Network Meta-analysisJonathan I Silverberg, H Chih-Ho Hong, Jacob P Thyssen, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|September 6, 2022
Rapid pruritus reduction with ruxolitinib cream treatment in patients with atopic dermatitisAndrew Blauvelt, Leon Kircik, Kim A Papp, et al.
The Journal of Dermatological Treatment|December 11, 2024
Real-world evidence on the benefits of optimal itch relief and skin clearance in atopic dermatitis management: a study from the TARGET-DERM AD registryJonathan I Silverberg, Brian M Calimlim, Ayman Grada, et al.
Pageof 67

Showing results (451-460 of 670) with videos related to

Sort By:
Pageof 67
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|November 10, 2023
Abrocitinib efficacy and safety in moderate-to-severe atopic dermatitis by race, ethnicity, and Fitzpatrick skin typeAndrew F Alexis, Jonathan I Silverberg, Zakiya P Rice, et al.
Journal of the American Academy of Dermatology|February 21, 2021
Metformin is associated with decreased risk of basal cell carcinoma: A whole-population case-control study from IcelandJonas A Adalsteinsson, Sonal Muzumdar, Reid Waldman, et al.
Journal of the American Academy of Dermatology|September 16, 2022
Itch-free state in patients with atopic dermatitis treated with ruxolitinib cream: A pooled analysis from two randomized phase 3 studiesAndrew Blauvelt, Jacek C Szepietowski, Kim Papp, et al.
Journal of the American Academy of Dermatology|February 18, 2026
The 487-gene expression profile test guides systemic therapy selection to improve outcomes for patients with atopic dermatitis: Results from a prospective trialJonathan I Silverberg, Lawrence F Eichenfield, April W Armstrong, et al.
The Journal of Dermatological Treatment|September 25, 2024
Disease burden and patient characteristics associated with systemic therapy utilization among adults with atopic dermatitis: data from CorEvitas Atopic Dermatitis RegistryJonathan I Silverberg, Linda Stein Gold, Seemal Desai, et al.
Journal of the American Academy of Dermatology|November 29, 2020
Anti-tumor necrosis factor therapy is associated with increased in situ squamous cell carcinoma of the skin: A population-based case-control studyJonas A Adalsteinsson, Sonal Muzumdar, Reid Waldman, et al.
Eclinicalmedicine|July 3, 2023
Efficacy and safety of topically applied therapeutic ammonia oxidising bacteria in adults with mild-to-moderate atopic dermatitis and moderate-to-severe pruritus: a randomised, double-blind, placebo-controlled, dose-ranging, phase 2b trialJonathan I Silverberg, Peter A Lio, Eric L Simpson, et al.
Dermatology and Therapy|April 18, 2022
Comparative Efficacy of Targeted Systemic Therapies for Moderate to Severe Atopic Dermatitis without Topical Corticosteroids: Systematic Review and Network Meta-analysisJonathan I Silverberg, H Chih-Ho Hong, Jacob P Thyssen, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|September 6, 2022
Rapid pruritus reduction with ruxolitinib cream treatment in patients with atopic dermatitisAndrew Blauvelt, Leon Kircik, Kim A Papp, et al.
The Journal of Dermatological Treatment|December 11, 2024
Real-world evidence on the benefits of optimal itch relief and skin clearance in atopic dermatitis management: a study from the TARGET-DERM AD registryJonathan I Silverberg, Brian M Calimlim, Ayman Grada, et al.
Pageof 67